REGN250502P510000
- 0.16
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $810
Regeneron Pharma Is Maintained at Buy by Guggenheim
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $587 to $940
Regeneron (REGN) Gets a Buy From Evercore ISI
Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940
Regeneron Pharma Is Maintained at Overweight by Wells Fargo
Evercore ISI Cuts Regeneron Pharmaceuticals' Price Target to $900 From $950
Wells Fargo Cuts Regeneron Pharmaceuticals' Price Target to $700 From $750
Jefferies Adjusts Regeneron Pharmaceuticals' Price Target to $914 Rom $936, Keeps Buy Rating
Regeneron Pharmaceuticals Analyst Ratings
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $633 From $768, Maintains Neutral Rating
RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Maintains Target Price $547
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $900
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $800
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $925
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Maintains Target Price $547
Baird Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $652
Regeneron Pharma Is Maintained at Neutral by Baird
Regeneron Pharma Price Target Cut to $652.00/Share From $759.00 by Baird